Missing/wrong data?
Log in to edit
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study
scientific article
Author/s
author: Guido Marcucci, Clara D. Bloomfield, Krzysztof Mrózek, Kati Maharry, Christian Thiede, Richard A. Larson, Peter Paschka
Work details
Publication date
June 16, 2008
-
-
Language
English
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.